Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD

被引:0
|
作者
Helen L. Reeves
Marco Y. W. Zaki
Christopher P. Day
机构
[1] Northern Institute for Cancer Research,Institute of Cellular Medicine
[2] Newcastle University,undefined
来源
关键词
Hepatocellular carcinoma; Obesity; Type 2 diabetes; Nonalcoholic fatty liver disease; PNPLA3; Macrophage; Inflammation; Autophagy;
D O I
暂无
中图分类号
学科分类号
摘要
Hepatocellular carcinoma (HCC) is the second commonest cause of cancer death worldwide. Rather than falling as a result of prevention and treatments for viral hepatitis, an increase is evident in developed nations consequent to the rising prevalence of obesity and type 2 diabetes mellitus (T2DM)—the two major risk factors for nonalcoholic fatty liver disease (NAFLD). The majority of patients with HCC complicating these conditions present with advanced disease as the tools for surveillance are inadequate, and the “at-risk” population is not well characterized. This review will summarize the epidemiological evidence linking obesity, T2DM, and NAFLD with HCC, what is known about the pathogenic mechanisms involved, as well as their relevance for clinicians managing patients at risk. There will also be an overview of the “unmet needs” surrounding this topic, with suggestions for the direction translational research should take in order to prevent progression of NAFLD to HCC, to improve early detection of HCC in those with NAFLD, as well as to improve outcomes for those affected.
引用
收藏
页码:1234 / 1245
页数:11
相关论文
共 50 条
  • [31] MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes
    Elemeery, Moustafa Nouh
    Mohamed, Marwa Anwar
    Madkour, Marwa Ahmed
    Shamseya, Mohammed Mohammed
    Issa, Noha Mahmoud
    Badr, Ahmed Noah
    Ghareeb, Doaa Ahmed
    Pan, Cheol-Ho
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (42) : 6322 - 6341
  • [32] NAFLD-related hepatocellular carcinoma
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (05): : 392 - 392
  • [33] Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, and Hepatocellular Carcinoma
    Noureddin, Mazen
    Rinella, Mary E.
    CLINICS IN LIVER DISEASE, 2015, 19 (02) : 361 - +
  • [34] Diabetes Mellitus, Obesity, and Hepatocellular Carcinoma: The Jury Is Still Out
    Shebl, Fatma M.
    El-Kamary, Samer S.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (09): : 2116 - 2117
  • [35] Postbiotics for the management of obesity, insulin resistance/type 2 diabetes and NAFLD. Beyond microbial viability
    Arellano-Garcia, Laura Isabel
    Portillo, Maria P.
    Martinez, J. Alfredo
    Courtois, Arnaud
    Milton-Laskibar, Inaki
    CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2024,
  • [36] Obesity and type 2 diabetes
    Maggio, CA
    Pi-Sunyer, FX
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2003, 32 (04) : 805 - +
  • [37] Obesity and type 2 diabetes
    Shulman, ST
    PEDIATRIC ANNALS, 2005, 34 (09): : 668 - 668
  • [38] Type 2 diabetes in obesity
    Chakaroun, R.
    DIABETOLOGE, 2014, 10 (07): : 581 - 582
  • [39] Obesity and type 2 diabetes
    Waine, C.
    NUTRITION BULLETIN, 2006, 31 (02) : 111 - 114
  • [40] Obesity and type 2 diabetes
    Toplak, Hermann
    Hoppichler, Friedrich
    Wascher, Thomas C.
    Schindler, Karin
    Ludvik, Bernhard
    WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 : S196 - S200